Comparison · NCT03926052-7303cc3a
LDX (Lisdexamfetamine Dimesylate) vs Placebo: Binge-Eating Relapse
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. LDX (Lisdexamfetamine Dimesylate) vs Placebo: Binge-Eating Relapse. Trial comparisons, record NCT03926052-7303cc3a. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03926052-7303cc3a
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.167 | 0.0584 | 0.392 | wilson | |
| Risk in group 2 | 0.087 | 0.0242 | 0.268 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0797 | -0.131 | 0.314 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.92 | 0.357 | 10.3 | log | |
| Odds ratio, group 1 over group 2 | 2.1 | 0.312 | 14.2 | log | |
| Number needed to treat, for one more participant with the outcome on LDX (Lisdexamfetamine Dimesylate) than on Placebo | 12.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | LDX (Lisdexamfetamine Dimesylate) | Lisdexamfetamine Dimesylate: Participants randomly assigned to this arm will receive 12 weeks of LDX medication. | 3 | 18 | OG000 |
| Group 2 | Placebo | Placebo: Participants randomly assigned to this arm will receive 12 weeks of an inactive placebo. | 2 | 23 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Binge-Eating Relapse
- Description
Relapse will be scored as a yes/no (categorical variable); this categorical variable will be based on frequency of binge-eating episodes assessed using the Eating Disorder Examination interview; Relapse category will be defined as ≥4 binge-eating episodes per month.
- Time frame
- 12 month follow-up
- Population
Source ClinicalTrials.gov
Trial
- Title
- Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Maintenance Treatment
- NCT number
- NCT03926052
- Phases
- PHASE3
- Conditions
- Binge-Eating Disorder, Obesity
- Interventions
- Lisdexamfetamine Dimesylate, Placebo
- Lead sponsor
- Yale University
- Results first posted
- 2025-12-17
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03926052?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03926052-7303cc3a